The efficacy of eprinomectin extended-release injection against Hypoderma spp. (Diptera: Oestridae) in cattle.

The efficacy of eprinomectin in an extended-release injection (ERI) formulation was determined in cattle harboring naturally acquired infestations of first- or second- and third-stage larvae of Hypoderma spp. in three studies conducted according to the same protocol in the USA (two studies) and Germany (one study). Thirty cattle sourced from herds with a history of Hypoderma infestation were included in each study. Cattle were formed into replicates of three animals each on the basis of pre-treatment anti-Hypoderma antibody titers. Within replicates each animal was randomly allocated to one of the following treatments: ERI vehicle (control) at 1 mL/50 kg bodyweight, administered once on Day 0; Eprinomectin 5% ERI at 1 mL/50 kg bodyweight (1.0 mg eprinomectin/kg), administered once on Day 0 (when larvae were expected to be first instars); or Eprinomectin 5% ERI at 1 mL/50 kg bodyweight (1.0 mg eprinomectin/kg), administered once when larvae were second or third instars (study dependent, Day 73, 119, or 140). Treatments were administered by subcutaneous injection in front of the shoulder. In all studies, emerging and/or expressed Hypoderma larvae were recovered, speciated, and counted and viability was determined. Eprinomectin LAI treatment was 100% (p<0.05) efficacious against first- and second- or third-stage larvae of Hypoderma bovis (two studies) and Hypoderma lineatum (one study). All animals accepted the treatment well. No adverse reaction to treatments was observed in any animal in any study.

Effect of omeprazole paste on gastric acid secretion in horses.

In a multicentre trial, 13 cannulated horses were treated orally once daily with a paste that delivered omeprazole at a dose of 4 and 5 mg/kg bwt in a 2-period crossover design to evaluate steady state gastric acid suppression. In each period, basal (unstimulated) and pentagastrin-stimulated gastric output were evaluated at 5-8 h after 5 doses, at 13-16 h after 10 doses, and at 21-24 h after 15 doses. Baseline data for gastric acid secretion were collected once for each horse in the month prior to initiation of omeprazole treatment. The inhibition of gastric acid secretion relative to baseline values, following treatment with omeprazole, were calculated and expressed as per cent. Pharmacokinetic data were also collected in this trial. At 4 mg/kg bwt, the oral paste formulation of omeprazole inhibited both basal and pentagastrin-stimulated gastric acid secretion by 99% at 5-8 h after treatment and by 83% (basal) and 90% (pentagastrin-stimulated) at 21-24 h. Inhibition following the administration of omeprazole at a dose of 5 mg/kg bwt was not significantly greater than when given at 4 mg/kg bwt. The results from this study could possibly lead to the development of an effective and practical antisecretory treatment of ulcer disease in horses.

Safety, acceptability and endoscopic findings in foals and yearling horses treated with a paste formulation of omeprazole for twenty-eight days.

A paste formulation of the H+,K(+)-ATPase inhibitor omeprazole was evaluated in Thoroughbred foals and yearlings for its safety and acceptability. Twenty foals age 11-16 weeks and 20 yearling horses age 15-17 months were included and gastroscopic examinations performed 1-3 days before and at the end of each trial. Lesions were scored on a scale of 0 to 3 and animals allocated based on endoscopic lesion score and sex, with 4 animals in each of 5 replicates. Dosages of 4 mg omeprazole/kg bwt or sham treatment were administered once daily for 28 days, from a syringe graduated in 50 lb (22.68 kg) increments, the amount of paste administered being rounded up to the nearest corresponding weight in pounds. Acceptability of the paste or sham treatment was assessed and recorded by the individual administering the treatment on the basis of the tolerance or resistance to insertion of the syringe into the mouth, administration of the paste and if the paste was swallowed or actively expelled by the animal. Safety was determined on the basis of daily observation recordings and physical examination findings during and at the conclusion of the trial. Treatment was judged to have been accepted for all 420 doses of omeprazole paste and all 140 sham doses given to foals during the trial and for 418/420 doses of paste and all 140 sham doses given to yearlings. Two doses of paste were entirely rejected by yearlings. On the initial endoscopic examination, lesions were observed in the gastric squamous epithelial mucosa in 4 foals and 3 yearlings, and single small, superficial erosions were seen in the gastric glandular mucosa of 2 foals. On the second examination there were small, superficial erosions in the squamous mucosa in 3 foals and 2 yearlings, multi-focal superficial erosions in 1 foal and 1 yearling, and 1 foal had large areas of erosion extending from the margo plicatus toward the dorsal fundus. No lesions in the glandular mucosa were seen in foals or yearlings. There were no significant differences (P < 0.05) in lesion scores between the beginning and the end of the trials in the omeprazole-treated or sham-treated groups of foals or yearlings. A paste formulation of omeprazole, administered at a dose of 4 mg/kg bwt once daily for 28 days, was determined to be highly acceptable to the foals and yearlings we studied, and no adverse effects attributable to the medication were noted.

Effects of omeprazole paste on healing of spontaneous gastric ulcers in horses and foals: a field trial.

A multicentre, blinded, randomised complete-block, field trial was conducted with 140 horses and foals age 4 weeks-28 years to determine if omeprazole paste is effective and safe in promoting healing of spontaneous gastric ulcers under a variety of field conditions and in different breeds and ages of horses. Horses in the study had gastric ulceration as determined by gastroscopy and were divided into replicates of 4 or 5 animals. One horse in each replicate was assigned randomly to receive an empty omeprazole syringe (sham-dosed control) and the remaining horses received omeprazole paste once daily for 28 days. Gastroscopy was repeated at the end of the study. Horses treated with omeprazole had significantly (P < 0.01) more improvement in ulcer scores at the end of the study compared with controls. Ulcers were improved in 32.4 and 99.0% of the control and omeprazole groups, respectively. Ulcers were completely healed in 8.9 and 86.7% of the control and omeprazole groups, respectively. Under typical field conditions, omeprazole was effective at enhancing healing of spontaneous gastric ulcers in horses of a variety of ages and breeds.

Efficacy of omeprazole paste in the treatment and prevention of gastric ulcers in horses.

Equine gastric ulcer syndrome (EGUS) is very common among performance horses, with a reported prevalence of approximately 90% in racehorses, and also > 50% in foals. Omeprazole, an acid pump inhibitor 5 times more potent than ranitidine, has been used with great success to treat EGUS. This multicentre study of Thoroughbred racehorses with endoscopically verified gastric ulcers was designed to demonstrate the efficacy of an equine oral paste formulation of omeprazole in the treatment and prevention of recurrence of EGUS. Of the 100 horses entered into the study, 25 were sham-dosed for the full 58 days of the study. The remaining 75 horses all received omeprazole paste, 4 mg/kg bwt/day once daily for 28 days. At Day 28, 25 of treated horses continued on this dosing regimen while 25 received a half dose (2 mg/kg bwt once daily) and 25 horses were sham-dosed. By Day 28, gastric ulcers were completely healed in 77% of omeprazole-treated horses, while 92% were significantly (P < 0.01) improved. In contrast, 96% of the sham-dosed horses still had gastric ulcers at Day 28. The improvement was maintained in horses that continued on either a full dose or half dose of omeprazole paste until Day 58. However, in those horses that were removed from omeprazole treatment at Day 28, the incidence and severity of the gastric ulcers at the end of the study were similar to those horses that did not receive the omeprazole paste. This study demonstrates that omeprazole paste, 4 mg/kg bwt per os, once daily, is highly effective in healing gastric ulcers in Thoroughbred racehorses and that either a full dose or half dose of omeprazole paste effectively prevents the recurrence of EGUS. The study also indicates that gastric ulcers in untreated horses did not demonstrate a significant rate of spontaneous healing.

Efficacy of eprinomectin against Hypoderma spp in cattle.

OBJECTIVE: To determine the efficacy of a topical formulation of eprinomectin against natural infestations of first (L1)-stage, and second and third (L2/L3)-stage larvae of Hypoderma spp. ANIMALS: 140 approximately 6- to 18-month-old cattle of various breeds. PROCEDURE: Cattle, selected from herds with high prevalence of Hypoderma infestation, were treated in 4 experiments: within each replicate, 1 animal received eprinomectin at a dosage of 500 micrograms/kg of body weight against first-stage larvae (L1). The second animal received the same treatment against second or third-stage larvae (L2/L3). The third animal served as an untreated control. In a fifth experiment, visible warbles were treated on half of the cattle. Remaining cattle served as vehicle-treated controls. In 1 experiment, warbles were examined from time of treatment until all lesions were resolved. In 4 experiments, emerging Hypoderma larvae were recovered, speciated, and enumerated, and viability was determined. RESULTS: Eprinomectin (500 micrograms/kg) efficacy was complete against L1. Hypoderma L2/L3 eradication approached 100% efficacy (1 live larva was recorded). Warbles in treated cattle resolved in a significantly shorter time than did those in controls. Adverse reactions related to treatment were not observed in any of the trials. CONCLUSIONS: Eprinomectin (500 micrograms/kg) applied topically was safe and highly efficacious for treatment of all larval stages of Hypoderma spp in these trials. CLINICAL RELEVANCE: Attributes of eprinomectin besides antiparasite efficacy allow treatment of all classes of cattle with no need for meat or milk withdrawal.

Nematocidal efficacy of eprinomectin, delivered topically, in naturally infected cattle.

OBJECTIVE: To assess the nematocidal efficacy of eprinomectin in naturally infected cattle. ANIMALS: 62 (31 eprinomectin-treated and 31 control) beef mixed-breed or Holstein cattle, either 6 to 11 or 48 to 96 months old. PROCEDURE: Cattle were housed 21 to 27 days before treatment to allow parasites to reach maturity. Animals were grouped by sex, ranked by weight, and randomly assigned to treatment group. Fecal flotation was done to identify cattle with intestinal nematode infections. Treatment groups were: 1--eprinomectin topical vehicle (1 ml/10 kg) and 2--eprinomectin topical solution (1 ml/10 kg). Cattle were euthanatized by replicate on day 14 or 15, and standard procedures were used to recover of pulmonary, abomasal, small intestinal, and large intestinal nematodes. RESULTS: Eprinomectin efficacy across all trials was 100% against adult Trichostrongylus axei, Haemonchus placei, Oesophagostomum radiatum, and Dictyocaulus viviparus, as well a fourth-stage larval Oes radiatum, Ostertagia ostertagi, Nematodirus helvetianus, and Cooperia spp. Efficacy against adult O ostertagi, Cooperia oncophora, C punctata, C surnabada, C spatulata, N helvetianus, Trichuris sp, and Trichuris fourth-stage larvae was 99.9 and 99.8, 99.6, 98.9, 98.3, 99.7, 97.8, and 84.3%, respectively. All results were significant (P < 0.01) except those for C spatulata. Adverse reactions were not observed. CONCLUSION AND CLINICAL RELEVANCE: Eprinomectin is a safe and effective nematocide against naturally acquired nematode infections in cattle when administered at a dosage of 500 micrograms/kg. Milk and meat withholding is not necessary when using this product.

Eprinomectin: a novel avermectin for control of lice in all classes of cattle.

Eight trials were conducted in the United States to determine the efficacy of eprinomectin applied topically against four common species of lice in cattle. In two dose titration trials, eprinomectin dosages of 125 to 750 mcg/kg body weight applied topically were compared to untreated controls. In dose confirmation studies, animals treated topically with eprinomectin applied at the rate of 500 mcg/kg were compared to vehicle-treated controls. Four species of lice were present in these trials: Linognathus vituli, Haematopinus eurysternus, Solenopotes capillatus, all sucking lice, and Damalinia (Bovicola) bovis, the cattle biting louse. Louse counts were made on six to nine predilection sites (the same number of sites in all animals in the same trial) prior to treatment. The same sites were counted again seven days after treatment and weekly thereafter until trial termination eight weeks after treatment. When no lice were found in the predilection sites, a modified whole body search was conducted. Each species of lice was present on at least six animals in each treatment group on at least one counting date in two or more trials. No lice were found on any animal treated topically with eprinomectin at a dosage of > or = 500 mcg/kg after 14 days posttreatment until termination of the trials eight weeks after treatment.

The efficacy of ivermectin (pour-on) against the eyeworms, Thelazia gulosa and Thelazia skrjabini in naturally infected cattle.

Sixteen crossbred beef cattle, 6-8 months of age, were used to determine the efficacy of ivermectin in a pour-on formulation against natural infections of Thelazia spp. Cattle were weighed on Day 0, ranked in descending order by bodyweight and sequentially paired. Within each pair, one animal was randomly assigned to an untreated control group, while the other animal was treated with a pour-on formulation of ivermectin applied topically at 1.0 ml per 10 kg bodyweight to achieve a dosage of 500 mg ivermectin kg-1 body weight. On Day 14 all animals in both treatment groups were slaughtered. The eyes and surrounding tissues were removed and examined for eyeworms. A total of 86 adult worms (74 Thelazia skrjabini and 12 Thelazia gulosa) were recovered from the untreated control animals. T. skrjabini was found in seven, and T. gulosa in three, of the eight untreated control animals. Two T. skrjabini, one from each of two animals, were found on the surface of the eyes of cattle that had received ivermectin treatment. The reduction in the geometric mean number for T. gulosa collected from treated animals was 100% (P > 0.1) relative to controls, and 97.02% (P = 0.0025) for T. skrjabini relative to controls.

Efficacy of ivermectin in a topical formulation against induced gastrointestinal and pulmonary nematode infections, and naturally acquired grubs and lice in cattle.

Efficacy of ivermectin in a topical formulation was evaluated in cattle against adult gastrointestinal and pulmonary nematode infections (experiment 1, n = 24), the 2nd- and 3rd-stage larvae of Hypoderma spp (experiment 2, n = 12), and the biting louse Damalinia bovis (experiment 3, n = 12). Nematode infections were induced and grubs and lice were naturally acquired. Treatments consisted of a single dose of ivermectin in a topical formulation of 200, 500, or 1,000 micrograms/kg of body weight in experiment 1 or 500 micrograms/kg in experiments 2 and 3. At 1,000 micrograms/kg, ivermectin was 100% effective against Ostertagia ostertagi, Trichostrongylus colubriformis, Oesophagostomum radiatum, Nematodirus helvetianus, Haemonchus placei, and Dictyocaulus viviparus and was greater than 99% effective against Cooperia oncophora, C punctata, and T axei. At 500 micrograms/kg, the efficacy was 100% against C oncophora, C punctata, O ostertagi, T axei, Oes radiatum, N helvetianus, Haem placei, and Dict viviparus and greater than 99% against T colubriformis. At 200 micrograms/kg, the efficacy was 100% against Oes radiatum, Haem placei, and Dict viviparus, greater than 99% for O ostertagi, 96% for C oncophora, 86% for C punctata, 90% for T axei, 85% for T colubriformis, and 71% for N helvetianus. At 500 micrograms/kg, ivermectin was highly effective against the grubs Hypoderma bovis and H lineatum and eliminated the louse Damalinia bovis.

Efficacy of ivermectin against the mange mite Sarcoptes scabiei var suis in pigs.

The efficacy of ivermectin administered by esophageal intubation in a single dose was evaluated against the mange mite Sarcoptes scabiei var suis in 24 naturally infested pigs. Six pigs were allocated to each of the 4 treatment groups. Control (group 1) pigs were given nonmedicated water, group 2 were given ivermectin at 300 micrograms/kg of body weight, group 3 were given ivermectin at 400 micrograms/kg, and group 4 were given ivermectin at 500 micrograms/kg. The pigs were examined for S scabiei before treatment and on days 7, 14, 21, and 28 after treatment. Of the 18 ivermectin-treated pigs, 10 had no live S scabiei recovered on day 7 after treatment, 16 had none on day 14, 18 had none on day 21, and 16 had none on day 28. All 6 nonmedicated control pigs had live S scabiei recovered on days 7 and 21, and 5 control pigs had mites on days 14 and 28. The single administration of ivermectin given by esophageal intubation was highly effective in reducing the number of S scabiei at all dose levels tested. The pooled ivermectin-treated groups had significantly (P less than 0.01) fewer mites than the control group on all posttreatment examination days. There were no statistically significant differences among the ivermectin dose levels.